Literature DB >> 11454944

Effect of perinatal buprenorphine exposure on development in the rat.

S E Robinson1, M J Wallace.   

Abstract

The developmental effects of exposure to various doses of buprenorphine, methadone, or water during the perinatal period were studied in the rat. Rats were exposed to buprenorphine (0.3, 1.0, or 3.0 mg/kg/day), methadone (9 mg/kg/day), and/or water prenatally, postnatally, or both pre- and postnatally, via maternally implanted osmotic minipumps. Fetal and maternal mortality and morbidity were assessed, as well as the acquisition of several developmental milestones, pup weight gain, precipitated withdrawal, and the antinociceptive effect of morphine. Although perinatal exposure to buprenorphine failed to produce severe maternal and fetal or neonatal mortality, it was associated with a significant amount of perinatal mortality and perturbations of pup development. Pups developed physical dependence to both drugs, as evidenced by the ability of naloxone challenge to precipitate withdrawal. Both drugs induced tolerance to the antinociceptive effects of morphine in the tail-flick test. The effects of buprenorphine varied with the dose used, and the highest dose did not always produce the greatest effect. There were some similarities between the effects of perinatal buprenorphine and perinatal methadone; however, differences were also observed between the effects of the two drugs, which may be related to the different affinities and efficacies of the drugs at different opioid receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454944

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

Review 2.  Effects of opioids on the parental brain in health and disease.

Authors:  James E Swain; S Shaun Ho; Helen Fox; David Garry; Susanne Brummelte
Journal:  Front Neuroendocrinol       Date:  2019-05-22       Impact factor: 8.606

Review 3.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

5.  Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine.

Authors:  Yao-Chang Chiang; Tsai-Wei Hung; Cynthia Wei-Sheng Lee; Jia-Ying Yan; Ing-Kang Ho
Journal:  J Biomed Sci       Date:  2010-06-07       Impact factor: 8.410

6.  Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice.

Authors:  John Oberdick; Yonghua Ling; Mitch A Phelps; Max S Yudovich; Karl Schilling; Wolfgang Sadee
Journal:  J Pharmacol Exp Ther       Date:  2016-05-05       Impact factor: 4.030

7.  Chronic in utero buprenorphine exposure causes prolonged respiratory effects in the guinea pig neonate.

Authors:  Michael Wallisch; Chinmayee V Subban; Rosemary T Nettleton; George D Olsen
Journal:  Neurotoxicol Teratol       Date:  2009-12-31       Impact factor: 3.763

8.  Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software.

Authors:  Hanna J Kulbeth; Saki Fukuda; Lisa K Brents
Journal:  Neurotoxicol Teratol       Date:  2021-01-30       Impact factor: 3.763

Review 9.  Endogenous and exogenous opioid effects on oligodendrocyte biology and developmental brain myelination.

Authors:  Brandon Velasco; Esraa Mohamed; Carmen Sato-Bigbee
Journal:  Neurotoxicol Teratol       Date:  2021-06-12       Impact factor: 4.071

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.